Stock Market Blog
Daily stock market analysis, trade alerts, and trading education from Ross Givens and the Traders Agency team.
This “Beaten Down” Sector is Surging
Software stocks are approaching record highs despite fears about AI. Ross explains how an old bearish opinion can keep you from spotting a fresh se
This Keeps Traders Stuck
Waiting to get your money back feels reasonable. But the price you paid can quietly replace every other reason for staying in a trade.
Chipotle Shares Fall Nearly 4% After Starbucks Denies Takeover Talk
A Starbucks spokesperson told CNBC the company is "not buying Chipotle." Chipotle shares fell nearly 4% in Monday morning trading, reversing gains from last week's Financial Times report.
Microsoft Says Maia 300 Will Handle Most AI Inference, Reducing Nvidia Reliance
Microsoft says its third-generation Maia 300 accelerator, entering production in 2027, will mainly handle AI inference, while Nvidia and AMD stay in its training mix, according to CNBC and other reports.
Using Stop-Loss Orders Effectively
Learn how to use stop-loss orders in stocks and forex, avoid common mistakes, and set smart trigger prices to protect every trade.
Energy Is Setting Up Again
Energy buyers are defending an old price ceiling while analysts raise profit estimates. Ross explains why former winners deserve another look after the excitement fades.
IonQ to Acquire Zero Trust Security Firm Elisity in All-Stock Deal Valued at Up to $1.3 Billion
IonQ said it signed a definitive agreement to acquire Zero Trust security firm Elisity in an all-stock deal valued at up to $1.3 billion, including up to $150 million in earnout consideration, with closing expected in Q4 2026.
Bausch + Lomb Taps Chairman Thomas Appio as Interim CEO; Companies Signal Higher 2026 EBITDA Outlook
Bausch + Lomb named chairman Thomas J. Appio interim CEO after Brent Saunders' departure, while both Bausch + Lomb and Bausch Health said they expect to raise full-year 2026 adjusted EBITDA (excluding Acquired IPR&D) guidance, per a joint release.
Bristol Myers Squibb Says Admilparant Clears Phase 3 Bar at Lower Dose in IPF Trial, Higher Dose Falls Short
Bristol Myers Squibb says its Phase 3 ALOFT-IPF trial met its primary endpoint at the 60 mg admilparant dose while the 120 mg arm missed statistical significance, with fuller data still to come.
Anthropic in Reported Talks to Buy Israeli AI Startup Decart at $6–7 Billion; Amazon Was an Earlier Suitor
Bloomberg, Reuters and Calcalist report Anthropic is in talks to acquire Israeli AI startup Decart at roughly $6 billion to $7 billion, with Amazon, Nvidia, SpaceX and Nebius linked to earlier stages of the process. No deal is signed.
Brent Crude Climbs Past $105 as Tanker Attacks in the Strait of Hormuz Compound Houthi Strikes on Saudi Arabia
Brent crude rose 0.73% to $105.48 a barrel as Reuters reported further Strait of Hormuz tanker attacks and a deadly Houthi strike on Riyadh's airport, while Goldman Sachs lifted its December Brent forecast to $90.
Nvidia in Early Talks to Acquire or Deepen Investment in Reflection AI, FT Reports
The Financial Times reports Nvidia is in early talks to acquire or further invest in open-weight AI startup Reflection AI, in which the FT says it has already invested $800 million.
Stop watching.
Start winning.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.
